A5007469769- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Sarcoidosis and Beryllium Toxicity Research
- Vasculitis and related conditions
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Inhalation and Respiratory Drug Delivery
- Tuberculosis Research and Epidemiology
- Systemic Sclerosis and Related Diseases
- Medical Imaging and Pathology Studies
- Pulmonary Hypertension Research and Treatments
- Lymphoma Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Waste Management and Environmental Impact
- Eosinophilic Disorders and Syndromes
- Mycobacterium research and diagnosis
- Asthma and respiratory diseases
- Peptidase Inhibition and Analysis
- Pneumocystis jirovecii pneumonia detection and treatment
- Respiratory Support and Mechanisms
- Occupational exposure and asthma
- Ultrasound in Clinical Applications
- Infectious Diseases and Mycology
- Otitis Media and Relapsing Polychondritis
- Otolaryngology and Infectious Diseases
- Atomic and Subatomic Physics Research
Instytut Gruźlicy i Chorób Płuc
2001-2020
Masih Daneshvari Hospital
2016-2020
Medical University of Warsaw
2019
National Institute of Public Health
2018
Institute of Cardiology
2017
Medical University of Lodz
2017
Abstract Background Patients with idiopathic pulmonary fibrosis (IPF) frequently have multiple comorbidities, which may influence survival but go under-recognised in clinical practice. We therefore report comorbidity, antifibrotic treatment use and of patients IPF observed the multi-national EMPIRE registry. Methods For this prospective cohort, demographics, causes death were analysed. Comorbidities noted by treating physician based on patient’s past medical history or as reported during...
Sarcoidosis is a systemic granulomatous disease which predominantly affects the lungs, although granulomas can also involve all other organs, including heart. Cardiac sarcoidosis (CS) may occur at any stage of and be cause sudden cardiac death, even in previously asymptomatic patient. The aim this study was to evaluate incidence CS large group patients diagnosed or followed up due sarcoidosis.We performed retrospective analysis our institution discharged with final diagnosis "sarcoidosis"...
Cardiac sarcoidosis (CS) is a life-threatening and underdiagnosed manifestation of the disease, which requires complicated expensive diagnostic pathway. There need for simple tool practitioners to determine risk CS without access specialized equipment. The aim study was prevalence in group patients diagnosed with or followed up because sarcoidosis. A secondary objective search factors associated heart involvement. We performed prospective case–control (screening analysis) consecutive...
Introduction: This document presents the Guideliness of Polish Respiratory Society (PTChP, Polskie Towarzystwo Chorób Płuc) for diagnosis and treatment idiopathic pulmonary fibrosis (IPF), developed by agroup experts. Material methods: The recommendations were in form answers to previously formulated questions concer-ning everyday diagnostic therapeutic challenges. They based on acurrent literature review using Grading Recommendations Assessment, Development Evaluation (GRADE) methodology....
Abstract Background Pirfenidone is an antifibrotic agent approved for the treatment of idiopathic pulmonary fibrosis (IPF). The drug available Polish patients with IPF since 2017. PolExPIR study aimed to describe real-world data (RWD) on experience pirfenidone therapy in respect safety and efficacy profiles. Methods This was a multicentre, retrospective, observational collecting clinical receiving from January 2017 September 2019 across 10 specialized centres Poland. Data collection included...
Objective. An analysis of subglottic stenosis (SGS) occurrence frequency in patients with granulomatosis polyangiitis (GPA) based on the time appearance clinical symptoms, and an assessment treatment effectiveness, particular intratracheal dilation-injection technique (IDIT). Methods. Review IDIT 34 SGS associated GPA. Results. developed 250 GPA (13.6%) was not reflective disease activity organs 15 (44%): 11 cases after 4 during immunosuppressive therapy (IST) when did have organ symptoms....
Sarcoidosis is a systemic granulomatous disease predominantly affecting the lungs, although granulomas can also involve all other organs. Fortunately, it often self-limiting and aggressive treatment not indicated in majority of cases. However, recommended when critical organs are affected or progressive. So far, there lack reliable information regarding frequency Caucasian population data discordant. The aim this study was to evaluate prevalence immune-modulating large cohort sarcoidosis...
Airway reversibility test (or bronchodilatation test) is performed routinely in the diagnosis of obstructive lung diseases. The results this may be helpful and differential asthma chronic pulmonary disease (COPD), but sometimes bring confusion. Unfortunately, nomenclature used for result not uniform, which also leads to Next reader will find an attempt order state affairs introduction a uniform nomenclature, would consistent with logic allow unambiguous classification facilitate future...
<b>Aims:</b> Many patients with idiopathic pulmonary fibrosis (IPF) have a delay in diagnosis and thus also treatment. We investigated whether such influenced survival treatment response to pirfenidone nitedanib. <b>Methods:</b> The retrospective study used data from European Multipartner IPF registry (EMPIRE). 1170 were divided the 2 groups: 1) diagnosed within (824) 2) after 12 months (346) initiation of symptoms. groups did not differ demographic data, proportion treated antifibrotic...
Introduction: Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and debilitating lung disease with median survival time of 3–5 years. For now, pirfenidone (PIR) nintedanib (NTB) are the only drugs that can slow down disease’s progression. In Poland, these drugs, although registered for legal use, had not been reimbursed IPF patients until end year 2016. Aim study was to assess what common practice in terms diagnosis treatment period before antifibrotic became available Poland....
Nintedanib is a disease-modifying agent licensed for the treatment of IPF. Data on Polish experience with nintedanib in IPF are lacking. The present study aimed to describe safety and efficacy profiles large real-world cohort patients This was multicenter, retrospective, observational treated between March 2018 October 2021. collection included baseline clinical characteristics, results pulmonary function tests (PFTs), six-minute walk test (6MWT). Longitudinal data PFTs, 6MWT, adverse drug...
Abstract Dyspnea and exercise intolerance are usually attributed to pulmonary disease in sarcoidosis patients. However, cardiac involvement may also be responsible for these symptoms. Data regarding the impact of heart on lung function (CS) is limited. The aim study was compare results tests (PFTs) patients with without involvement. We performed a retrospective analysis PFTs group both evaluated by cardiovascular magnetic resonance (CMR) study. period between May 2008 April 2016. included...
Background Currently, only two drugs have been shown to modify the inevitable natural history of idiopathic pulmonary fibrosis (IPF). Changes in reimbursement policy for antifibrotic Poland led availability pirfenidone from January 2017 and nintedanib March 2018 treatment Polish patients with IPF. This study aimed evaluate possible changes shortcomings clinical practice standards IPF era access therapy Poland. Methods A real-world data survey was performed among physicians attending...
Sarcoidosis is a chronic multiorgan granulomatous disease of unknown etiology, which most often involves the lungs and intrathoracic lymph nodes [...]